Advanced Search

 

Study ID Status Title Patient Level Data
NN210005 Completed A Phase I, Multicenter, Randomized, Parallel, Double-Blinded Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Four Oral Dosage Regimens of GW695634G Monotherapy Versus Placebo Over 10 days in ART-Naive HIV-1 Infected Adults.
NOS102512 Completed A Randomized, Single-Blind, Single-Attack, Placebo-Controlled, Adaptive Design Study to Assess the Safety and Efficacy of doses of 5-180 mg of the iNOS inhibitor GW274150 in the Treatment of Acute Migraine during the Mild Headache Phase
NOS103325 Completed A multicentre, two-part, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, tolerability and pharmacokinetics of the iNOS inhibitor GW274150 administered up to 120mg daily for 12 Weeks in the prophylactic treatment of migraine.
NUC 30956 Completed AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (presumed pre-core mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN.
O7921353 Completed A Single-dose, Two-centre, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Two Kinds of AlbendazoleTablet Formulations in Healthy Chinese Adult Males
OEF0701 Completed A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis
OFA110867 Completed Clinical phase I/IIA study of subcutaneously administration of Ofatumumab in Rheumatoid Arthritis patients on stable dose Methotrexate
OHB20001 Completed A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy, Safety and Tolerability of Two Doses (20mg and 60mg) of a Once-Daily Oral Formulation of GW353162 in Subjects with Major Depressive Disorder for a Treatment period of Eight Weeks
OHB20002 Completed A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects with Major Depressive Disorder Over an Eight-Week Treatment Period.
OHB20003 Completed A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (40-60mg) Versus Placebo in Subjects with Major Depressive Disorder Over an Eight-Week Treatment Period.
OLA103920 Completed A randomised, single and repeat dose, double-blind, placebo controlled study to assess the safety, tolerability and pharmacokinetics of GSK615915 in healthy volunteers and mild asthmatics.
OM5 program (Reliant) Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Omacor Therapy in Hypertriglyceridemic Subjects Treated with Antara, followed by an 8-week extension Study Listed on ClinicalStudyDataRequest.com
OM6 program (Reliant) Completed A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Omacor and Simvastatin Therapy in Hypertriglyceridemic Subjects Study Listed on ClinicalStudyDataRequest.com
OM8 Afib Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation Study Listed on ClinicalStudyDataRequest.com
OM9L Completed A Randomized, Double-Blind, Placebo-Controlled, Forced Titration Study to Assess the Efficacy and Safety of Omacor, Co-Administered with Open-Label Atorvastatin Therapy, in Hypertriglyceridemic Subjects Study Listed on ClinicalStudyDataRequest.com
OMB110911 Active, Not Recruiting A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil versus Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia
OMB111148 Completed An open-label phase I study of ofatumumab (GSK1841157) in Japanese patients with CD20 positive follicular lymphoma or chronic lymphocytic leukemia
OPB107935 Completed An open-label, randomized, crossover study to estimate the formulation effect on the relative bioavailability of single dose oral SB-742510 in healthy subjects
OPL104226 Completed A prospective observational study for the psychometric validation of a patient-reported questionnaire in acute exacerbations of chronic obstructive pulmonary disease (AECOPD)
OPS106400 Completed A three-part first time in human study to evaluate safety, tolerability, pharmacokinetics and food effect of single oral doses of GSK580416 in healthy adult subjects
OPS108221 Terminated A three part study in healthy adult subjects to evaluate the safety, tolerability and pharmacokinetics of repeat escalating oral doses of GSK580416; the safety, tolerability, and pharmacokinetics of GSK580416 following a loading dose regimen; and the effect of ketoconazole on the pharmacokinetics of GSK580416
OTA105101 Completed An open-label, two period study to determine the excretion balance and pharmacokinetics of [14C]-GSK221149A, administered as single doses of an oral solution and an intravenous infusion to healthy female volunteers
OTA105256 Completed A randomized, double-blind, placebo-controlled, dose ranging study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously and to investigate the pharmacokinetics of GSK221149A administered orally to healthy, pregnant females with uncomplicated pre-term labor between 300/7 and 356/7 weeks’ gestation Study Listed on ClinicalStudyDataRequest.com
OTA106004 Terminated A two-part, open-label, cross-over study to assess the pharmacokinetics of GSK221149 following single oral doses of various modified release formulations and a solution in healthy adult subjects
OTB109039 Completed A Two-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of GSK557296 in a Randomized, Single-Blind, Placebo-Controlled, Dose-Rising Design, and to Evaluate the Effect of Food on Single Oral Doses of GSK557296 in Healthy Adult Subjects

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.